Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug-Sep;28(7-8):683-699.
doi: 10.1080/1061186X.2020.1797754. Epub 2020 Aug 12.

Pharmacotherapy in COVID-19 patients: a review of ACE2-raising drugs and their clinical safety

Saghir Akhtar  1 , Ibrahim F Benter  2 , Mohammed I Danjuma  1   3 , Suhail A R Doi  1 , Syed S Hasan  4 , Abdella M Habib  1
Affiliations
Review

Pharmacotherapy in COVID-19 patients: a review of ACE2-raising drugs and their clinical safety

Saghir Akhtar et al. J Drug Target. 2020 Aug-Sep.

Abstract

The COVID-19 pandemic is caused by the severe acute-respiratory-syndrome-coronavirus-2 that uses ACE2 as its receptor. Drugs that raise serum/tissue ACE2 levels include ACE inhibitors (ACEIs) and angiotensin-II receptor blockers (ARBs) that are commonly used in patients with hypertension, cardiovascular disease and/or diabetes. These comorbidities have adverse outcomes in COVID-19 patients that might result from pharmacotherapy. Increasing ACE2 could potentially increase the risk of infection, severity or mortality in COVID-19 or it might be protective as it forms angiotensin-(1-7) which exhibits anti-inflammatory/anti-oxidative effects and prevents diabetes- and/or hypertension-induced end-organ damage. Thus, there existed clinical uncertainty. Here, we review studies implicating 15 classes of drugs in increasing ACE2 levels in vivo and the available literature on the clinical safety of these drugs in COVID-19 patients. Further, in a re-analysis of clinical data from a meta-analysis of 9 studies, we show that ACEIs/ARBs usage was not associated with an increased risk of all-cause mortality. Literature suggests that ACEIs/ARBs usage generally appears to be clinically safe though their use in severe COVID-19 patients might increase the risk of acute renal injury. For definitive clarity, further clinical and mechanistic studies are needed in assessing the safety of all classes of ACE2 raising medications.

Keywords: ACE inhibitors; ACE2; Ang-(1-7); COVID-19; DPP-4 inhibitors; GLP-1 agonists; Mineralocorticoid receptor inhibitors; RAAS; angiotensin receptor blockers; statins.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

MeSH terms

Substances

LinkOut - more resources